A retrospective analysis of preemptive pharmacogenomic testing in 22,918 individuals from China

Abstract

AbstractBackgroundPharmacogenomics (PGx) examines the influence of genetic variation on drug responses. With more and more Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines published, PGx is gradually shifting from the reactive testing of single gene toward the preemptive testing of multiple genes. But the profile of PGx genes, especially for the intra‐country diversity, is not well understood in China.MethodsWe retrospectively collected preemptive PGx testing data of 22,918 participants from 20 provinces of China, analyzed frequencies of alleles, genotypes and phenotypes of pharmacogenes, predicted drug responses for each participant, and performed comparisons between different provinces.Results and ConclusionAfter analyzing 15 pharmacogenes from CPIC guidelines of 31 drugs, we found that 99.97% of individuals may have an atypical response to at least one drug; the participants carry actionable genotypes leading to atypical dosage recommendation for a median of eight drugs. Over 99% of the participants were recommended a decreased warfarin dose based on genetic factors. There were 20 drugs with high‐risk ratios from 0.18% to 58.25%, in which clopidogrel showed the highest high‐risk ratio. In addition, the high‐risk ratio of rasburicase in GUANGDONG (risk ratio (RR) = 13.17, 95%CI:4.06–33.22, p < 0.001) and GUANGXI (RR = 23.44, 95%CI:8.83–52.85, p < 0.001) were significantly higher than that in all provinces. Furthermore, the diversity we observed among 20 provinces suggests that preemptive PGx testing in different geographical regions in China may need to pay more attention to specific genes. These results emphasize the importance of preemptive PGx testing and provide essential evidence for promoting clinical implementation in China.